Literature DB >> 17921436

Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2.

Hyun Jeong Jeong1, Hyun-Sook Lee, Kyung-Sup Kim, Yoon-Kyoung Kim, Dojun Yoon, Sahng Wook Park.   

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a member of the subtilases that promotes the internalization and degradation of LDL receptor in liver and thereby controls the level of LDL cholesterol in plasma. Here, we show that the expression of PCSK9 in HepG2 cells is completely dependent on the absence or presence of sterols. The minimal promoter region of the PCSK9 gene contains a sterol-regulatory element (SRE), which makes the transcription of PCSK9 dependent on sterols. Expression of nuclear forms of sterol-regulatory element binding protein-1 (SREBP-1) and SREBP-2 dramatically increased the promoter activity of PCSK9. In vitro-translated nuclear forms of SREBPs showed interactions with SRE, whereas mutations in SRE abolished their binding. In vivo studies in mice showed that Pcsk9 protein and mRNA were decreased significantly by fasting and increased by refeeding. However, supplementation with 2% cholesterol in the diet prevented the increase in Pcsk9. The amounts of Pcsk9 mRNA in livers of refed mice showed correlated regulation by the changes in the nuclear form of Srebp-2. In summary, it is suggested that the expression of PCSK9 is regulated by sterol at the transcriptional level in HepG2 cells and that both SREBP-1 and SREBP-2 can transcriptionally activate PCSK9 via SRE in its proximal promoter region in vitro. However, in vivo, it is suggested that the sterol-dependent regulation of PCSK9 is mediated predominantly by SREBP-2.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17921436     DOI: 10.1194/jlr.M700443-JLR200

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  104 in total

1.  Reduction in PCSK9 levels induced by anacetrapib: an off-target effect?

Authors:  Philip J Barter; Fatiha Tabet; Kerry-Anne Rye
Journal:  J Lipid Res       Date:  2015-09-16       Impact factor: 5.922

2.  Peroxisome Proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression.

Authors:  Yajun Duan; Yuanli Chen; Wenquan Hu; Xiaoju Li; Xiaoxiao Yang; Xin Zhou; Zhinan Yin; Deling Kong; Zhi Yao; David P Hajjar; Lin Liu; Qiang Liu; Jihong Han
Journal:  J Biol Chem       Date:  2012-05-16       Impact factor: 5.157

3.  The epigenetic drug 5-azacytidine interferes with cholesterol and lipid metabolism.

Authors:  Steve Poirier; Samaneh Samami; Maya Mamarbachi; Annie Demers; Ta Yuan Chang; Dennis E Vance; Grant M Hatch; Gaétan Mayer
Journal:  J Biol Chem       Date:  2014-05-22       Impact factor: 5.157

4.  The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated Hypercholesterolemia.

Authors:  Mary E Haas; Amy E Levenson; Xiaowei Sun; Wan-Hui Liao; Joseph M Rutkowski; Sarah D de Ferranti; Valerie A Schumacher; Philipp E Scherer; David J Salant; Sudha B Biddinger
Journal:  Circulation       Date:  2016-07-05       Impact factor: 29.690

5.  Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters.

Authors:  Bin Dong; Minhao Wu; Hai Li; Fredric B Kraemer; Khosrow Adeli; Nabil G Seidah; Sahng Wook Park; Jingwen Liu
Journal:  J Lipid Res       Date:  2010-01-04       Impact factor: 5.922

Review 6.  From evolution to revolution: miRNAs as pharmacological targets for modulating cholesterol efflux and reverse cholesterol transport.

Authors:  Alberto Dávalos; Carlos Fernández-Hernando
Journal:  Pharmacol Res       Date:  2013-02-19       Impact factor: 7.658

Review 7.  The PCSK9 decade.

Authors:  Gilles Lambert; Barbara Sjouke; Benjamin Choque; John J P Kastelein; G Kees Hovingh
Journal:  J Lipid Res       Date:  2012-07-17       Impact factor: 5.922

8.  Isolation and characterization of the circulating truncated form of PCSK9.

Authors:  Bomie Han; Patrick I Eacho; Michael D Knierman; Jason S Troutt; Robert J Konrad; Xiaohong Yu; Krista M Schroeder
Journal:  J Lipid Res       Date:  2014-04-28       Impact factor: 5.922

9.  Plasma PCSK9 preferentially reduces liver LDL receptors in mice.

Authors:  Aldo Grefhorst; Markey C McNutt; Thomas A Lagace; Jay D Horton
Journal:  J Lipid Res       Date:  2008-03-19       Impact factor: 5.922

10.  Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine.

Authors:  Hai Li; Bin Dong; Sahng Wook Park; Hyun-Sook Lee; Wei Chen; Jingwen Liu
Journal:  J Biol Chem       Date:  2009-08-17       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.